lanthionine ketimine has been researched along with Parkinson Disease in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goshima, Y; Hasegawa, M; Hensley, K; Kotaka, K; Masukawa, D; Nagai, J; Ohshima, T; Takahashi, M; Togashi, K; Yazawa, A | 1 |
1 other study(ies) available for lanthionine ketimine and Parkinson Disease
| Article | Year |
|---|---|
Lanthionine ketimine ester improves outcome in an MPTP-induced mouse model of Parkinson's disease via suppressions of CRMP2 phosphorylation and microglial activation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acids, Sulfur; Animals; Disease Models, Animal; Dopaminergic Neurons; Esters; Mice; Mice, Inbred C57BL; Microglia; Parkinson Disease; Phosphorylation; Substantia Nigra | 2020 |